Nucleus Network has recently opened its expanded facility in Sydney for Phase I clinical trials. Credit: Nucleus Network. There is no denying that Australia hits above its weight class in early ...
Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results